Sangamo Therapeutics, Inc. (SGMO)

Sangamo Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	39.2	45.2	100.44	178.87	131.33	80.43
Short-Term Investments	-	35.8	177.19	197.68	510.09	282.05
Cash & Short-Term Investments	39.2	81	277.63	376.55	641.42	362.47
Cash Growth	-70.33%	-70.82%	-26.27%	-41.29%	76.96%	-9.41%
Accounts Receivable	10.5	0.92	3.68	6.01	5.22	36.91
Other Receivables	-	0.4	0.79	0.35	1.04	0.68
Receivables	10.5	1.33	4.47	6.36	6.26	37.59
Prepaid Expenses	8.43	12	18.22	15.86	11.99	5.41
Total Current Assets	58.13	94.33	300.33	398.77	659.67	405.47
Property, Plant & Equipment	36.91	52.87	125.53	124.7	112.37	107.22
Long-Term Investments	-	-	29.85	88.17	50.53	21.83
Goodwill	-	-	37.55	39.7	42.8	39.27
Other Intangible Assets	-	-	50.73	53.76	58.13	53.16
Long-Term Deferred Tax Assets	-	-	1.12	1.06	0.47	-
Other Long-Term Assets	16.22	18.13	17.41	15.76	14.58	10.57
Total Assets	111.26	165.32	562.51	721.92	938.55	637.52
Accounts Payable	19.79	15.26	22.42	9.76	12.55	6.67
Accrued Expenses	22.6	16.15	33.39	28.39	30.66	21.28
Current Portion of Leases	-	4.59	4.12	4.03	3.69	3.21
Current Unearned Revenue	0.77	-	51.78	85.71	91.64	38.71
Other Current Liabilities	-	11.73	-	-	5	-
Total Current Liabilities	43.16	47.73	111.71	127.89	143.55	69.87
Long-Term Leases	27.73	33.52	38.99	44.06	38.4	41.19
Long-Term Unearned Revenue	-	-	109.38	166.78	245.05	81.43
Long-Term Deferred Tax Liabilities	-	-	6.27	6.65	7.19	6.57
Other Long-Term Liabilities	1.24	1.19	1.21	1.22	7.01	5.71
Total Liabilities	72.13	82.43	267.55	346.58	441.18	204.78
Common Stock	2.09	1.78	1.67	1.46	1.42	1.16
Additional Paid-In Capital	1,522	1,492	1,450	1,334	1,269	1,091
Retained Earnings	-1,481	-1,406	-1,149	-956.27	-777.98	-656.99
Comprehensive Income & Other	-4.22	-4.6	-8.4	-3.99	5.42	-2.45
Total Common Equity	39.13	82.89	294.96	375.34	498.23	432.55
Minority Interest	-	-	-	-	-0.87	0.19
Shareholders' Equity	39.13	82.89	294.96	375.34	497.37	432.74
Total Liabilities & Equity	111.26	165.32	562.51	721.92	938.55	637.52
Total Debt	27.73	38.1	43.11	48.08	42.09	44.41
Net Cash (Debt)	11.47	42.9	264.37	416.64	649.87	339.9
Net Cash Growth	-88.19%	-83.77%	-36.55%	-35.89%	91.19%	-15.05%
Net Cash Per Share	0.06	0.25	1.71	2.88	4.83	3.03
Filing Date Shares Outstanding	208.35	178.91	168.48	145.97	143.25	116.02
Total Common Shares Outstanding	208.35	178.13	166.79	145.92	142.06	115.97
Working Capital	14.97	46.6	188.62	270.88	516.12	335.6
Book Value Per Share	0.19	0.47	1.77	2.57	3.51	3.73
Tangible Book Value	39.13	82.89	206.68	281.88	397.31	340.13
Tangible Book Value Per Share	0.19	0.47	1.24	1.93	2.80	2.93
Machinery	-	47.02	54.72	49.85	30.7	21.82
Construction In Progress	-	1.09	14.77	4.73	12.09	5.9
Leasehold Improvements	-	29.81	30.57	21.97	15.95	13.89

Source: S&P Capital IQ. Standard template. Financial Sources.